Oculis Holding AG Ordinary shares 2026 Global Healthcare Conference

Thank you, Jack. Pleasure to be here.

Yes, of course. Oculis is a biopharma company, listed in Nasdaq since March 2023. It is a portfolio company with two advanced programs, which are both actually in the phase III, in registration stage. The first one, which is Licaminlimab, is focusing on subset of dry eye, which is called TNFR1 dry eye patient, with the precision medicine type of approach, where we are genotyping patient before treating them. We expect the readout in end of the year, December or January 2027. It is really coming a matter of weeks or months now. The second asset is called Privosegtor. Privosegtor is a neuroprotective agent. It was tested in an indication which is called acute optic neuritis. The benefit of acute optic neuritis, it really offers two shot on goal. One, it is an unmet medical need. We don't have anything in optic neuritis, which is an orphan indication.

The second benefit is a very solid proof of concept for neuroprotection. Why? Because retina is actually brain tissue.

What works in the retina in terms of neuroprotection should work in the brain. We had amazing results, I have to say, from the phase II. We are now in phase III. We got a breakthrough from FDA, prime from EMA, and the product is in registration trial and randomizing, basically.

Yeah. Licaminlimab went into three clinical trials: DE-1, DE-2, DE-3. Two in symptoms, one in sign, all positive. But what we did in DE-2 in an exploratory manner, we explored how we can identify patient who will respond better to TNF inhibition. And we saw actually on the exploratory manner that this patient had sevenfold better symptoms improvement versus all comers. Then we, in a pre-specified manner in Dry Eye 3, we took the same biomarker, we tested it in signs, and in fact, a patient with this genotype showed five times better in signs improvement. Therefore, it just consistent between signs and symptoms. What we are doing now in the first phase III, and totally aligned with FDA, is we are actually testing patient, selecting the patient based on this genotype.

Two-third of the patient will have this genotype, and the primary endpoint will be improvement of VAS, which is a symptom score in TNFR1 DD patient, and the secondary endpoint will be improvement of VAS in all comers.

Okay. If we compare in symptoms in a phase II, we had a 4-point different in VAS score in all comers.

We had 28-point difference in TNFR1 patient. So 4 point is typical to any dry eye product available today. Therefore, in a phase III, if we deliver just the double, just 8 point Yeah it will be the double of anything we see in the market.